Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Kits, Reagents), LNP Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing) - Global Forecast to 2029
Report Code: BT 9141 Sep, 2024, by marketsandmarkets.com
The global lipid nanoparticles market is projected to reach USD 350.5 million by 2029 from USD 271.8 million in 2024, at a CAGR of 5.2% during the forecast period. The global lipid nanoparticles services market is projected to reach USD 238.1 million by 2029 from USD 135.5 million in 2024, at a CAGR of 11.9% during the forecast period.
The growth of the lipid nanoparticles market can be attributed to factors such as the development of lipid nanoparticle-based pharmaceuticals and the expanding application of lipid nanoparticles in anti-cancer and mRNA-based therapies. However, stringent regulations imposed by the regulatory organizations and issues associated with the formulation of lipid nanoparticles are expected to restrain market growth.
LIPID Nanoparticles Market- Global Forecast to 2029
To know about the assumptions considered for the study, Request for Free Sample Report
LIPID Nanoparticles Services Market- Global Forecast to 2029
Attractive Opportunities in the Lipid Nanoparticles Market
Global Lipid Nanoparticles Market Dynamics
DRIVERS: Increasing development of lipid nanoparticle-based pharmaceuticals
R&D in lipid nanoparticle technologies is conducted through developments in lipid formulations, improvement of manufacturing techniques, and progress in characterization methodologies. With these developments, it is now possible for scientists to generate lipid nanoparticles that have improved stability, enhanced biocompatibility, and increased drug-loading capacity, opening up their applications in drug delivery. Other targeted ways of delivery researchers are looking into include surface modification using peptides, antibodies, or ligands with lipid nanoparticles. The delivery techniques focus on enhancing treatment outcomes, specificity, and efficiency for drug delivery in innumerable diseases, such as cancer, infectious diseases, and neurological disorders. Due to targeted drug delivery, LNP pharmaceuticals can synergize therapeutic effects, offering enhanced patient outcomes.
RESTRAINTS: Stringent regulatory requirements for LNP drugs
Regulatory organizations such as the US FDA and the EMA are expected to restrain the broader adoption of LNP drugs owing to stringent regulatory guidelines for the commercialization of drugs. Elaborate studies on biodistribution, toxicity, and immunogenicity in animal models are expected to comply with such laws, which require stringent preclinical evaluations regarding safety, usefulness, and pharmacokinetics. It is also critical in clinical research to comply with Good Clinical Practice (GCP) principles. Due to such regulatory requirements, market entry timeframes are often extensive, delaying the potential development of the lipid nanoparticles market for raw materials and services.
OPPORTUNITIES: Growing demand for advanced drug delivery systems
Advanced delivery systems are in high demand, particularly those that help combat the inadequacies of conventional treatment options. The rising demand for advanced drug delivery technologies has expanded opportunities for lipid nanoparticles within the market. Drug delivery systems enhance the solubility of drugs, improve bioavailability, release kinetics control, and target tissue/cell delivery. The adaptability of lipid nanoparticles allows the development of new formulations and combination therapies exploiting positive interactions that improve treatment efficiency for better patient outcomes. Combination treatments, for example, can act on multiple disease pathways. This can be made possible simultaneously by engineering the lipid nanoparticles to co-deliver multiple therapeutic drugs in a single platform. The technology of lipid nanoparticles has also demonstrated its adaptability to clinical use, being scalable from the clinical successes of small lipid-nanoparticle-based mRNA vaccines for COVID-19, attracting heavy investments from pharmaceutical, biotechnology, and academic institutions worldwide.
CHALLENGES: Issues associated with LNP formulation
The development, stability, and performance of LNP drugs are collectively decided on several factors. These complexities involve the selection of lipids with appropriate physical-chemical properties while retaining biodegradability, biocompatibility, and controlled release properties; these lipid compositions must be acceptably modified to get expected. The control is usually through optimization of drug-to-lipid ratios, encapsulation techniques, and formulation characteristics. Maintaining long-term stability is critical since nanoparticles are subjected to oxidation, hydrolysis, and aggregation as degradation processes. Ensuring long-term stability during storage and administration is a significant challenge that calls for formulation techniques such as adding antioxidants or stabilizers, as lipid nanoparticles are vulnerable to oxidation, hydrolysis, and aggregation as degradation processes. Maintaining constant particle size distribution, drug loading efficiency, and batch repeatability presents difficulties when production is scaled up from laboratory to commercial scale. Overcoming these obstacles requires multidisciplinary cooperation, advanced analytical methods, and computational modeling to create novel lipid nanoparticle formulations that ensure strict safety, efficacy, and stability.
Ecosystem Analysis
The lipid nanoparticles market ecosystem comprises raw material suppliers, LNP manufacturers, and end users such as pharmaceutical & biotechnology companies, academic & research institutes, and CDMOs.
By product, the ionizable lipids segment accounted for the largest lipid nanoparticles market share in 2023.
By product, the lipid nanoparticles market is segmented into ionizable lipids, PEGylated lipids, neutral lipids, phospholipids, kits & reagents, and other formulation materials. There is an increase in ionizable lipids; the main constituent of lipid nanoparticles (LNP) for drug delivery. Ionizable lipids have shown encouraging results in the production of mRNA vaccines. For instance, the COVID-19 pandemic vaccines by Pfizer-BioNTech’s BNT162b2 and Moderna’s mRNA-1273 are notable examples that rely on ionizable LNP lipids to be administered. The market for mRNA vaccines is expected to grow significantly, thus reflecting continued high demand for ionizable lipids.
By commercial application, the lipid nanoparticles market was dominated by the COVID-19 application in 2023.
Based on commercial application, the lipid nanoparticles market is segmented into polyneuropathy and COVID-19. In 2023, the COVID-19 segment accounted for the largest share of the lipid nanoparticles market. As LNPs enhance the stability and distribution of messenger RNA (mRNA), they are increasingly utilized in COVID-19 vaccines.
North America was the largest regional segment for the lipid nanoparticles market in 2023.
The global lipid nanoparticles market is segmented into six major regions—North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. In 2023, North America accounted for the largest share of the market, followed by Europe and the Asia Pacific. Factors such as the rising number of drug development projects, the presence of a well-established healthcare market, significant spending on R&D activities, and the presence of key manufacturers are the key factors that contribute to market growth in North America.
To know about the assumptions considered for the study, download the pdf brochure
Key Market Players
The key players in the lipid nanoparticles market include Avanti Polar Lipids (Croda International plc) (US), Merck KGaA (Germany), Evonik Industries AG (Germany), FUJIFILM Pharmaceuticals U.S.A., Inc. (Japan), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF Corporation (Japan), Precision NanoSystems (Canada), Gattefossé (France), Acuitas Therapeutics (Canada), Creative Biolabs (US), Curapath (Spain), Lipoid GmbH (Germany), Nanocs, Inc. (US), MedKoo Biosciences, Inc. (US), Polysciences, Inc. (US), BIOVECTRA (Canada), IOI Oleo GmbH (Germany), Ascendia Pharmaceuticals (US), Curia Global, Inc. (US), and Vernal Biosciences (US), among others.
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
Request Sample Scope of the Report
Get online access to the report on the World's First Market Intelligence Cloud
- Easy to Download Historical Data & Forecast Numbers
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
|
Report Metric |
Details |
|
Market Size |
2022–2029 |
|
Base Year |
2023 |
|
Forecast Period |
2024–2029 |
|
Forecast Units |
Value (USD) |
|
Segments Covered |
Product, LNP Type, Molecule Type, Application, End User, Service Type, End User (Services) |
|
Geographies Covered |
North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa |
This report categorizes the lipid nanoparticles market into the following segments:
Lipid Nanoparticles Market, by Product
- Ionizable lipids
- PEGylated lipids
- Neutral lipids
- Phospholipids
- Other Formulation Materials
Lipid Nanoparticles Market, by LNP Type
- Solid lipid Nanoparticles (SLNs)
- Nanostructured lipid Carriers (NLCs)
- Other Types
Lipid Nanoparticles Market, by Molecule Type
- siRNA
- mRNA
- Other Molecules
Lipid Nanoparticles Market, by Application
-
Commercial
- Polyneuropathy
- Covid-19
-
Clinical
- Covid-19
- Cancer
- Other Clinical Applications
Lipid Nanoparticles Market, by End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- CDMO’s
Lipid Nanoparticles Services Market, by Service Type
- Formulation Development Services
- Manufacturing Services
- Other Services
Lipid Nanoparticles Services Market, by End User (Services)
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
Lipid Nanoparticles Market, by Region
-
North America
- US
- Canada
-
Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe (RoE)
-
Asia Pacific (APAC)
- Japan
- China
- India
- South Korea
- Australia
- Rest of Asia Pacific (RoAPAC)
-
Latin America
- Brazil
- Mexico
- RoLATAM
-
Middle East
- GCC
- Rest of Middle East
- Africa
Recent Developments
- In April 2024, NOF CORPORATION collaborated with Phosphorex to deliver lipid nanoparticle compositions using a unique ionizable lipid, the COATSOME8 SA Series.
- In February 2024, Evonik Industries AG collaborated with the University of Mainz to commercialize new PEG lipids formulated for nucleic acid delivery.
Frequently Asked Questions (FAQ):
Who are the key players in the lipid nanoparticles market?
Key players in the lipid nanoparticles market include Avanti Polar Lipids (Croda International plc (US), Merck KGaA (Germany), Evonik Industries AG (Germany), Fujifilm Pharmaceuticals U.S.A., Inc. (US), Nippon Fine Chemical (Japan), Recipharm AB (Sweden), Emergent (US), EUROAPI (France), Cayman Chemical (US), CordenPharma (Switzerland), NOF CORPORATION (Japan), Precision NanoSystems (Canada), Gattefossé (France), Acuitas Therapeutics (Canada), Creative Biolabs (US), Curapath (Spain), Lipoid GmbH (Germany), Nanocs, Inc. (US), MedKoo Biosciences, Inc. (US), Polysciences, Inc. (US), BIOVECTRA (Canada), Ascendia Pharmaceuticals (US), Curia Global, Inc. (US), IOI Oleo GmbH (Germany), and Vernal Biosciences (US).
Which product segment dominates the lipid nanoparticles market?
The ionizable lipids segment dominated the lipid nanoparticles market. The large share of this segment can be attributed to the rising adoption of Mrna-based vaccines. .
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS (Page No. - 51)
4.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW
4.2 ASIA PACIFIC: LNP RAW MATERIALS & SERVICES MARKET, BY PRODUCT
4.3 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 LNP RAW MATERIALS MARKET, BY END USER, 2023
4.5 LNP SERVICES MARKET, BY END USER, 2023
5 MARKET OVERVIEW (Page No. - 55)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Increasing use of lipid nanoparticles in anti-cancer research
5.2.1.2 High uptake in RNA-based therapeutic research
5.2.1.3 Growing government focus on R&D for LNP-based drugs
5.2.2 RESTRAINTS
5.2.2.1 Stringent regulatory requirements
5.2.3 OPPORTUNITIES
5.2.3.1 Growing demand for advanced drug delivery systems
5.2.4 CHALLENGES
5.2.4.1 Challenges associated with LNP formulation
5.2.5 INDUSTRY TRENDS
5.2.5.1 Growing preference for personalized medicine and targeted drug delivery
5.2.5.2 Advancements in mRNA-based vaccine technology
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.4 PRICING ANALYSIS
5.4.1 INDICATIVE SELLING PRICE OF LNP PRODUCTS, BY KEY PLAYER
5.4.2 INDICATIVE SELLING PRICE, BY PRODUCT
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.7.1 LNP RAW MATERIALS & SERVICES MARKET: ROLE IN ECOSYSTEM
5.8 TECHNOLOGY ANALYSIS
5.8.1 KEY TECHNOLOGIES
5.8.1.1 Nanotechnology-based drug delivery
5.8.1.2 Nucleic acid delivery
5.8.2 COMPLEMENTARY TECHNOLOGIES
5.8.2.1 Drug encapsulation techniques
5.8.2.2 Surface modification and functionalization technologies
5.8.3 ADJACENT TECHNOLOGIES
5.8.3.1 Biotechnology & genetic engineering technologies
5.8.3.2 Nanotechnology-based formulation techniques
5.9 PATENT ANALYSIS
5.9.1 PATENTS FILED, BY DOCUMENT TYPE, 2014–2023
5.9.2 INNOVATION AND PATENT APPLICATIONS
5.9.3 TOP APPLICANTS
5.10 KEY CONFERENCES & EVENTS, 2024–2025
5.11 REGULATORY LANDSCAPE
5.11.1 REGULATORY SCENARIO
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.12 PORTER’S FIVE FORCES ANALYSIS
5.12.1 DEGREE OF COMPETITION
5.12.2 BARGAINING POWER OF SUPPLIERS
5.12.3 BARGAINING POWER OF BUYERS
5.12.4 THREAT OF SUBSTITUTES
5.12.5 THREAT OF NEW ENTRANTS
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR LIPID NANOPARTICLES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
5.14 KEY BUYING CRITERIA
5.14.1 BUYING CRITERIA FOR LNP RAW MATERIALS
5.14.2 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
5.14.3 BUYING CRITERIA FOR LNP SERVICES
5.14.4 BUYING CRITERIA FOR LNP SERVICES, BY END USER
5.15 INVESTMENT & FUNDING SCENARIO
5.16 IMPACT OF GENERATIVE AI ON LNP RAW MATERIALS & SERVICES MARKET
6 LNP RAW MATERIALS MARKET, BY PRODUCT (Page No. - 90)
6.1 INTRODUCTION
6.2 IONIZABLE LIPIDS
6.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET
6.3 PEGYLATED LIPIDS
6.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND
6.4 NEUTRAL LIPIDS
6.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
6.5 PHOSPHOLIPIDS
6.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH
6.6 KITS & REAGENTS
6.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET
6.7 OTHER FORMULATION MATERIALS
7 LNP RAW MATERIALS MARKET, BY LNP TYPE (Page No. - 102)
7.1 INTRODUCTION
7.2 SOLID LIPID NANOPARTICLES (SLNS)
7.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET
7.3 NANOSTRUCTURED LIPID CARRIERS (NLCS)
7.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET
7.4 OTHER LNP TYPES
8 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE (Page No. - 111)
8.1 INTRODUCTION
8.2 SIRNA
8.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET
8.3 MRNA
8.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET
8.4 OTHER MOLECULES
9 LNP RAW MATERIALS MARKET, BY APPLICATION (Page No. - 121)
9.1 INTRODUCTION
9.2 COMMERCIAL APPLICATIONS
9.2.1 POLYNEUROPATHY
9.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand
9.2.2 COVID-19
9.2.2.1 Enhanced stability and distribution of mRNA to drive market
9.3 CLINICAL APPLICATIONS
9.3.1 COVID-19
9.3.1.1 Threat of evolving emerging variants to fuel uptake
9.3.2 CANCER
9.3.2.1 Increasing focus on oncology therapeutics to drive market
9.3.3 OTHER CLINICAL APPLICATIONS
10 LNP RAW MATERIALS MARKET, BY END USER (Page No. - 140)
10.1 INTRODUCTION
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET
10.3 ACADEMIC & RESEARCH INSTITUTES
10.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET
10.4 CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS (CDMOS)
10.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET
11 LNP SERVICES MARKET, BY SERVICE TYPE (Page No. - 149)
11.1 INTRODUCTION
11.2 FORMULATION DEVELOPMENT SERVICES
11.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET
11.3 MANUFACTURING SERVICES
11.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY AND VACCINE DEVELOPMENT TO DRIVE MARKET
11.4 OTHER SERVICES
12 LNP SERVICES MARKET, BY END USER (Page No. - 154)
12.1 INTRODUCTION
12.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET
12.3 ACADEMIC & RESEARCH INSTITUTES
12.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH
13 LNP RAW MATERIALS & SERVICES MARKET, BY REGION (Page No. - 158)
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.2.2 US
13.2.2.1 High pharmaceutical R&D expenditure to drive market
13.2.3 CANADA
13.2.3.1 Growing focus on personalized medicine to drive market
13.3 EUROPE
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2 GERMANY
13.3.2.1 Rising development activities for LNP production to drive market
13.3.3 UK
13.3.3.1 Pioneering research programs for drug delivery systems to boost demand
13.3.4 FRANCE
13.3.4.1 Government funding for proteomics and genomics research to support market growth
13.3.5 ITALY
13.3.5.1 Growth in life sciences research to propel market
13.3.6 SPAIN
13.3.6.1 Growing demand for cancer therapeutics to drive market
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2 CHINA
13.4.2.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market
13.4.3 JAPAN
13.4.3.1 Demand for LNP-based mRNA vaccines to fuel market
13.4.4 INDIA
13.4.4.1 Growth in pharmaceutical industry to drive market
13.4.5 SOUTH KOREA
13.4.5.1 Rising number of clinical trials to boost demand
13.4.6 AUSTRALIA
13.4.6.1 Growing requirement for innovative drug delivery systems to propel market
13.4.7 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2 BRAZIL
13.5.2.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake
13.5.3 MEXICO
13.5.3.1 Large target patient population and demand for novel drug delivery technology to drive market
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
13.6.2 GCC COUNTRIES
13.6.2.1 Economic & healthcare expansion to support market growth
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
14 COMPETITIVE LANDSCAPE (Page No. - 238)
14.1 INTRODUCTION
14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
14.3 REVENUE ANALYSIS
14.4 MARKET SHARE ANALYSIS
14.4.1 LNP SERVICES MARKET
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
14.5.5.1 Company footprint
14.5.5.2 Product footprint
14.5.5.3 Application footprint
14.5.5.4 Service type footprint
14.5.5.5 Region footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON ANALYSIS
14.9 COMPETITIVE SCENARIO
14.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
14.9.2 DEALS
14.9.3 EXPANSIONS
15 COMPANY PROFILES (Page No. - 261)
15.1 KEY PLAYERS
15.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC)
15.1.1.1 Business overview
15.1.1.2 Products/Services offered
15.1.1.3 Recent developments
15.1.1.3.1 Deals
15.1.1.4 MnM view
15.1.1.4.1 Key strengths
15.1.1.4.2 Strategic choices
15.1.1.4.3 Weaknesses & competitive threats
15.1.2 MERCK KGAA
15.1.2.1 Business overview
15.1.2.2 Products/Services offered
15.1.2.3 Recent developments
15.1.2.3.1 Deals
15.1.2.3.2 Expansions
15.1.2.4 MnM view
15.1.2.4.1 Key strengths
15.1.2.4.2 Strategic choices
15.1.2.4.3 Weaknesses & competitive threats
15.1.3 EVONIK INDUSTRIES AG
15.1.3.1 Business overview
15.1.3.2 Products/Services offered
15.1.3.3 Recent developments
15.1.3.3.1 Deals
15.1.3.4 MnM view
15.1.3.4.1 Key strengths
15.1.3.4.2 Strategic choices
15.1.3.4.3 Weaknesses & competitive threats
15.1.4 NIPPON FINE CHEMICAL
15.1.4.1 Business overview
15.1.4.2 Products/Services offered
15.1.4.3 MnM view
15.1.4.3.1 Key strengths
15.1.4.3.2 Strategic choices
15.1.4.3.3 Weaknesses & competitive threats
15.1.5 NOF CORPORATION
15.1.5.1 Business overview
15.1.5.2 Products/Services offered
15.1.5.3 Recent developments
15.1.5.3.1 Deals
15.1.5.4 MnM view
15.1.5.4.1 Key strengths
15.1.5.4.2 Strategic choices
15.1.5.4.3 Weaknesses & competitive threats
15.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC. (FUJIFILM HOLDINGS CORPORATION)
15.1.6.1 Business overview
15.1.6.2 Products/Services offered
15.1.6.3 Recent developments
15.1.6.3.1 Expansions
15.1.7 PRECISION NANOSYSTEMS (CYTIVA)
15.1.7.1 Business overview
15.1.7.2 Products/Services offered
15.1.7.3 Recent developments
15.1.7.3.1 Product/Service launches
15.1.7.3.2 Deals
15.1.7.3.3 Expansions
15.1.8 RECIPHARM AB
15.1.8.1 Business overview
15.1.8.2 Products/Services offered
15.1.8.3 Recent developments
15.1.8.3.1 Deals
15.1.9 EMERGENT
15.1.9.1 Business overview
15.1.9.2 Products/Services offered
15.1.9.3 Recent developments
15.1.9.3.1 Deals
15.1.10 EUROAPI
15.1.10.1 Business overview
15.1.10.2 Products/Services offered
15.1.11 CAYMAN CHEMICAL
15.1.11.1 Business overview
15.1.11.2 Products/Services offered
15.1.12 CORDENPHARMA
15.1.12.1 Business overview
15.1.12.2 Products/Services offered
15.1.12.3 Recent developments
15.1.12.3.1 Product/Service launches
15.1.12.3.2 Deals
15.1.12.3.3 Expansions
15.1.13 GATTEFOSSÉ
15.1.13.1 Business overview
15.1.13.2 Products/Services offered
15.1.14 ACUITAS THERAPEUTICS
15.1.14.1 Business overview
15.1.14.2 Products/Services offered
15.1.14.3 Recent developments
15.1.14.3.1 Deals
15.1.15 IOI OLEO GMBH
15.1.15.1 Business overview
15.1.15.2 Products/Services offered
15.2 OTHER PLAYERS
15.2.1 CREATIVE BIOLABS
15.2.2 CURAPATH
15.2.3 LIPOID GMBH
15.2.4 NANOCS INC.
15.2.5 MEDKOO BIOSCIENCES, INC.
15.2.6 POLYSCIENCES INC.
15.2.7 BIOVECTRA
15.2.8 ASCENDIA PHARMACEUTICALS
15.2.9 CURIA GLOBAL, INC.
15.2.10 VERNAL BIOSCIENCES
16 APPENDIX (Page No. - 308)
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS
LIST OF TABLES (398 TABLES)
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
TABLE 2 RISK ANALYSIS
TABLE 3 LNP RAW MATERIALS & SERVICES MARKET: IMPACT ANALYSIS
TABLE 4 INDICATIVE PRICING OF LNP PRODUCTS, BY KEY PLAYER
TABLE 5 INDICATIVE PRICING OF LNP PRODUCTS, BY TYPE
TABLE 6 PATENTS FILED, 2014–2023
TABLE 7 INDICATIVE LIST OF PATENTS IN LNP RAW MATERIALS & SERVICES MARKET
TABLE 8 LNP RAW MATERIALS & SERVICES MARKET: LIST OF CONFERENCES & EVENTS (2024−2025)
TABLE 9 REGULATORY SCENARIO
TABLE 10 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 11 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 14 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 15 LNP RAW MATERIALS & SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 16 BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
TABLE 17 LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 18 IONIZABLE LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 19 NORTH AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 20 EUROPE: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 21 ASIA PACIFIC: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 22 LATIN AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 23 MIDDLE EAST: IONIZABLE LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 24 PEGYLATED LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 25 NEUTRAL LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 NORTH AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 27 EUROPE: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 28 ASIA PACIFIC: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 29 LATIN AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 30 MIDDLE EAST: NEUTRAL LIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 31 PHOSPHOLIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 32 NORTH AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 33 EUROPE: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 34 ASIA PACIFIC: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 35 LATIN AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 36 MIDDLE EAST: PHOSPHOLIPIDS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 37 KITS & REAGENTS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 38 OTHER FORMULATION MATERIALS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 39 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 40 SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 41 NORTH AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 42 EUROPE: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 43 ASIA PACIFIC: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 44 LATIN AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 45 MIDDLE EAST: SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 46 NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 NORTH AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 48 EUROPE: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 50 LATIN AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 51 MIDDLE EAST: NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 52 OTHER LNP TYPES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 53 NORTH AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 54 EUROPE: OTHER LNP TYPES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 55 ASIA PACIFIC: OTHER LNP TYPES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 56 LATIN AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 57 MIDDLE EAST: OTHER LNP TYPES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 58 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 59 LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2022–2029 (USD MILLION)
TABLE 60 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 61 EUROPE: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 62 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 63 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 64 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2022–2029 (USD MILLION)
TABLE 65 LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2022–2029 (USD MILLION)
TABLE 66 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 67 EUROPE: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 69 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 70 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2022–2029 (USD MILLION)
TABLE 71 LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2022–2029 (USD MILLION)
TABLE 72 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 73 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 75 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 76 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2022–2029 (USD MILLION)
TABLE 77 LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 78 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 79 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 80 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 82 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 83 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 84 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 85 LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2022–2029 (USD MILLION)
TABLE 86 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 87 EUROPE: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 89 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 90 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2022–2029 (USD MILLION)
TABLE 91 LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY REGION, 2022–2029 (USD MILLION)
TABLE 92 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 93 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 94 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 95 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 96 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19 (COMMERCIAL APPLICATIONS), BY REGION, 2022–2029 (USD MILLION)
TABLE 97 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 98 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 99 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 100 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 101 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 102 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 104 LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY REGION, 2022–2029 (USD MILLION)
TABLE 105 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 106 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 107 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 108 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 109 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY REGION, 2022–2029 (USD MILLION)
TABLE 110 LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
TABLE 111 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 112 EUROPE: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 113 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 114 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 115 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
TABLE 116 LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
TABLE 117 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 118 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 120 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 121 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY REGION, 2022–2029 (USD MILLION)
TABLE 122 LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 123 LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 124 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 125 EUROPE: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 126 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 127 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 128 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 129 LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 130 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 131 EUROPE: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 132 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 133 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 134 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 135 LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 136 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 137 EUROPE: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 139 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 140 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2022–2029 (USD MILLION)
TABLE 141 LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 142 FORMULATION DEVELOPMENT SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 143 MANUFACTURING SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 144 OTHER SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 145 LNP SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 146 LNP SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
TABLE 147 LNP SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION)
TABLE 148 LNP RAW MATERIALS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 149 LNP SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 150 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 151 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 152 NORTH AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 153 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 154 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 155 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 156 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 157 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 158 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 159 NORTH AMERICA: LNP SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 160 US: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 161 US: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 162 US: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 163 US: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 164 US: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 165 US: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 166 US: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 167 CANADA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 168 CANADA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 169 CANADA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 170 CANADA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 171 CANADA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 172 CANADA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 173 CANADA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 174 EUROPE: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 175 EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 176 EUROPE: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 177 EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 178 EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 179 EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 180 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 181 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 182 EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 183 EUROPE: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION)
TABLE 184 GERMANY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 185 GERMANY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 186 GERMANY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 187 GERMANY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 188 GERMANY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 189 GERMANY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 190 GERMANY: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 191 UK: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 192 UK: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 193 UK: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 194 UK: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 195 UK: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 196 UK: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 197 UK: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 198 FRANCE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 199 FRANCE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 200 FRANCE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 201 FRANCE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 202 FRANCE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 203 FRANCE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 204 FRANCE: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 205 ITALY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 206 ITALY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 207 ITALY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 208 ITALY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 209 ITALY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 210 ITALY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 211 ITALY: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 212 SPAIN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 213 SPAIN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 214 SPAIN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 215 SPAIN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 216 SPAIN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 217 SPAIN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 218 SPAIN: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 219 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 220 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 221 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 222 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 223 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 224 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 225 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 226 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 227 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 228 ASIA PACIFIC: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 229 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 230 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 231 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 232 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 233 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 234 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 235 ASIA PACIFIC: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION)
TABLE 236 CHINA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 237 CHINA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 238 CHINA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 239 CHINA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 240 CHINA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 241 CHINA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 242 CHINA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 243 JAPAN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 244 JAPAN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 245 JAPAN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 246 JAPAN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 247 JAPAN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 248 JAPAN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 249 JAPAN: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 250 INDIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 251 INDIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 252 INDIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 253 INDIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 254 INDIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 255 INDIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 256 INDIA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 257 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 258 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 259 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 260 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 261 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 262 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 263 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 264 AUSTRALIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 265 AUSTRALIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 266 AUSTRALIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 267 AUSTRALIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 268 AUSTRALIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022–2029 (USD MILLION)
TABLE 269 AUSTRALIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 270 AUSTRALIA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 271 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 272 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 273 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 274 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 275 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 276 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 277 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 278 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 279 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 280 LATIN AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 281 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 282 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 283 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 284 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 285 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 286 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 287 LATIN AMERICA: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION)
TABLE 288 BRAZIL: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 289 BRAZIL: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 290 BRAZIL: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 291 BRAZIL: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 292 BRAZIL: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 293 BRAZIL: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 294 BRAZIL: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 295 MEXICO: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 296 MEXICO: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 297 MEXICO: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 298 MEXICO: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 299 MEXICO: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 300 MEXICO: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 301 MEXICO: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 302 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 303 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 304 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 305 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 306 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 307 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 308 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 309 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY REGION, 2022–2029 (USD MILLION)
TABLE 310 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 311 MIDDLE EAST: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 312 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 313 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 314 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 315 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 316 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 317 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 318 MIDDLE EAST: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION)
TABLE 319 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 320 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 321 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 322 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 323 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022–2029 (USD MILLION)
TABLE 324 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 325 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 326 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 327 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 328 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 329 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 330 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE,2022–2029 (USD MILLION)
TABLE 331 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 332 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 333 AFRICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2022–2029 (USD MILLION)
TABLE 334 AFRICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2022–2029 (USD MILLION)
TABLE 335 AFRICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2022–2029 (USD MILLION)
TABLE 336 AFRICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2022–2029 (USD MILLION)
TABLE 337 AFRICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
TABLE 338 AFRICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 339 AFRICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2022–2029 (USD MILLION)
TABLE 340 AFRICA: LNP RAW MATERIALS MARKET, BY END USER, 2022–2029 (USD MILLION)
TABLE 341 AFRICA: LNP SERVICES MARKET BY END USER, 2022–2029 (USD MILLION)
TABLE 342 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
TABLE 343 LNP RAW MATERIALS MARKET: DEGREE OF COMPETITION
TABLE 344 LNP SERVICES MARKET: TOP SERVICE PROVIDERS (2023)
TABLE 345 LNP RAW MATERIALS & SERVICES MARKET: PRODUCT FOOTPRINT
TABLE 346 LNP RAW MATERIALS & SERVICES MARKET: APPLICATION FOOTPRINT
TABLE 347 LNP RAW MATERIALS & SERVICES MARKET: SERVICE TYPE FOOTPRINT
TABLE 348 LNP RAW MATERIALS & SERVICES MARKET: REGION FOOTPRINT
TABLE 349 LNP RAW MATERIALS & SERVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 350 LNP RAW MATERIALS & SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
TABLE 351 LNP RAW MATERIALS & SERVICES MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021−JUNE 2024
TABLE 352 LNP RAW MATERIALS & SERVICES MARKET: DEALS, JANUARY 2021−JUNE 2024
TABLE 353 LNP RAW MATERIALS & SERVICES MARKET: EXPANSIONS, JANUARY 2021−JUNE 2024
TABLE 354 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY OVERVIEW
TABLE 355 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCTS/SERVICES OFFERED
TABLE 356 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): DEALS, JANUARY 2021–JUNE 2024
TABLE 357 MERCK KGAA: COMPANY OVERVIEW
TABLE 358 MERCK KGAA: PRODUCTS/SERVICES OFFERED
TABLE 359 MERCK KGAA: DEALS, JANUARY 2021–JUNE 2024
TABLE 360 MERCK KGAA: EXPANSIONS, JANUARY 2021–JUNE 2024
TABLE 361 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
TABLE 362 EVONIK INDUSTRIES AG: PRODUCTS/SERVICES OFFERED
TABLE 363 EVONIK INDUSTRIES AG: DEALS, JANUARY 2021–JUNE 2024
TABLE 364 NIPPON FINE CHEMICAL CO., LTD.: COMPANY OVERVIEW
TABLE 365 NIPPON FINE CHEMICAL CO., LTD.: PRODUCTS/SERVICES OFFERED
TABLE 366 NOF CORPORATION: COMPANY OVERVIEW
TABLE 367 NOF CORPORATION: PRODUCTS/SERVICES OFFERED
TABLE 368 NOF CORPORATION: DEALS, JANUARY 2021–JUNE 2024
TABLE 369 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY OVERVIEW
TABLE 370 FUJIFILM PHARMACEUTICALS U.S.A., INC.: PRODUCTS/SERVICES OFFERED
TABLE 371 FUJIFILM PHARMACEUTICALS U.S.A., INC.: EXPANSIONS, JANUARY 2021–JUNE 2024
TABLE 372 PRECISION NANOSYSTEMS: COMPANY OVERVIEW
TABLE 373 PRECISION NANOSYSTEMS: PRODUCTS/SERVICES OFFERED
TABLE 374 PRECISION NANOSYSTEMS: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JUNE 2024
TABLE 375 PRECISION NANOSYSTEMS: DEALS, JANUARY 2021–JUNE 2024
TABLE 376 PRECISION NANOSYSTEMS: EXPANSIONS, JANUARY 2021–JUNE 2024
TABLE 377 RECIPHARM AB: COMPANY OVERVIEW
TABLE 378 RECIPHARM AB: PRODUCTS/SERVICES OFFERED
TABLE 379 RECIPHARM AB: DEALS, JANUARY 2021–JUNE 2024
TABLE 380 EMERGENT: COMPANY OVERVIEW
TABLE 381 EMERGENT: PRODUCTS/SERVICES OFFERED
TABLE 382 EMERGENT: DEALS, JANUARY 2021–JUNE 2024
TABLE 383 EUROAPI: COMPANY OVERVIEW
TABLE 384 EUROAPI: PRODUCTS/SERVICES OFFERED
TABLE 385 CAYMAN CHEMICAL: COMPANY OVERVIEW
TABLE 386 CAYMAN CHEMICAL: PRODUCTS/SERVICES OFFERED
TABLE 387 CORDENPHARMA: COMPANY OVERVIEW
TABLE 388 CORDENPHARMA: PRODUCTS/SERVICES OFFERED
TABLE 389 CORDENPHARMA: PRODUCT/SERVICE LAUNCHES, JANUARY 2021–JUNE 2024
TABLE 390 CORDENPHARMA: DEALS, JANUARY 2021–JUNE 2024
TABLE 391 CORDENPHARMA: EXPANSIONS, JANUARY 2021–JUNE 2024
TABLE 392 GATTEFOSSÉ: COMPANY OVERVIEW
TABLE 393 GATTEFOSSÉ: PRODUCTS/SERVICES OFFERED
TABLE 394 ACUITAS THERAPEUTICS: COMPANY OVERVIEW
TABLE 395 ACUITAS THERAPEUTICS: PRODUCTS/SERVICES OFFERED
TABLE 396 ACUITAS THERAPEUTICS: DEALS, JANUARY 2021–JUNE 2024
TABLE 397 IOI OLEO GMBH: COMPANY OVERVIEW
TABLE 398 IOI OLEO GMBH: PRODUCTS/SERVICES OFFERED
LIST OF FIGURES (53 FIGURES)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 LNP RAW MATERIALS & SERVICES MARKET: BREAKDOWN OF PRIMARIES
FIGURE 3 LNP RAW MATERIALS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 4 LNP SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2023
FIGURE 5 MARKET SIZE ESTIMATION (RAW MATERIALS): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 6 MARKET SIZE ESTIMATION (SERVICES): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023
FIGURE 7 ILLUSTRATIVE EXAMPLE OF NOF CORPORATION: REVENUE SHARE ANALYSIS (2023)
FIGURE 8 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
FIGURE 10 LNP RAW MATERIALS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 11 LNP SERVICES MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 12 DATA TRIANGULATION METHODOLOGY
FIGURE 13 LNP RAW MATERIALS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
FIGURE 14 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 16 LNP RAW MATERIALS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
FIGURE 17 LNP RAW MATERIALS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 18 LNP SERVICES MARKET, BY SERVICE TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 19 LNP SERVICES MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 20 LNP RAW MATERIALS & SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 21 INCREASING USE OF LIPID NANOPARTICLES IN RNA-BASED THERAPIES TO PROPEL LNP RAW MATERIALS MARKET
FIGURE 22 IONIZABLE LIPIDS ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
FIGURE 23 JAPAN IS EXPECTED TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 24 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 25 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
FIGURE 26 LNP RAW MATERIALS & SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR LNP RAW MATERIAL MANUFACTURERS
FIGURE 28 SUPPLY CHAIN ANALYSIS: DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
FIGURE 29 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE
FIGURE 30 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING FORMULATION DEVELOPMENT & MANUFACTURING PHASE
FIGURE 31 LNP RAW MATERIALS & SERVICES MARKET: ECOSYSTEM ANALYSIS
FIGURE 32 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR LIPID NANOPARTICLE PATENTS (JANUARY 2014–DECEMBER 2023)
FIGURE 33 LNP RAW MATERIALS & SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 34 NORTH AMERICA: LNP RAW MATERIALS MARKET SNAPSHOT
FIGURE 35 ASIA PACIFIC: LNP RAW MATERIALS MARKET SNAPSHOT
FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2019–2023 (USD MILLION)
FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET (2023)
FIGURE 38 LNP RAW MATERIALS & SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 39 LNP RAW MATERIALS & SERVICES MARKET: COMPANY FOOTPRINT
FIGURE 40 LNP RAW MATERIALS & SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 41 EV/EBITDA OF KEY VENDORS
FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 43 LNP RAW MATERIALS & SERVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 44 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY SNAPSHOT (2023)
FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2023)
FIGURE 46 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2023)
FIGURE 47 NIPPON FINE CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2023)
FIGURE 48 NOF CORPORATION: COMPANY SNAPSHOT (2023)
FIGURE 49 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY SNAPSHOT (2023)
FIGURE 50 RECIPHARM AB: COMPANY SNAPSHOT (2023)
FIGURE 51 EMERGENT: COMPANY SNAPSHOT (2023)
FIGURE 52 EUROAPI: COMPANY SNAPSHOT (2023)
FIGURE 53 IOI OLEO GMBH: COMPANY SNAPSHOT (2023)
This research study was conducted with analysis of both secondary sources and primary research inputs. Secondary sources involved key suppliers & customer filings, investor documents, clinical trial directories, industry associations, among others to collect information for the analysis of the global lipid nanoparticles market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key suppliers and customers, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the lipid nanoparticles market. The secondary sources used for this study include United States Food and Drug Administration (US FDA), National Cancer Institute (NCI), National Institutes of Health (NIH), Organization for Economic Co-operation and Development (OECD), Centers for Medicare and Medicaid Services (CMS), International Monetary Fund (IMF), German Federal Ministry of Education and Research (BMBF), UK Research and Innovation (UKRI), GLOBOCAN, Indian Council of Medical Research (ICMR), Korea Advanced Institute of Science and Technology (KAIST), Korea Drug Development Fund (KDDF), Centre of Excellence in Convergent Bio-Nano Science and Technology (CBNS), Association of Southeast Asian Nations (ASEAN), International Agency for Research on Cancer (IARC), World Economic Situation and Prospects (WESP), research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global lipid nanoparticles market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the lipid nanoparticles market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the lipid nanoparticles business of leading players have been determined through primary and secondary research to arrive at the overall lipid nanoparticles market.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
- Additionally, to arrive at the lipid nanoparticles market for each product, the lipid nanoparticles business shares of leading players for each product / service category were also gathered from secondary sources to the extent available. In some instances, the shares of lipid nanoparticles businesses were ascertained through a detailed analysis of various parameters, including product portfolios and market positioning.
- Individual shares or revenue estimates were validated through expert interviews.
To know about the assumptions considered for the study, Request for Free Sample Report
Top-down Approach
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
lipid nanoparticles (LNPs) are tiny particles, typically measuring between 20 to 200 nanometers, made from various lipids. They are designed to encapsulate and deliver therapeutic agents, such as nucleic acids (mRNA, siRNA), small Molecule Types, and proteins, to specific cells or tissues. LNPs are composed of a mix of lipids, including phospholipids, cholesterol, and ionizable lipids, which self-assemble to form structures that protect and transport the therapeutic payload.
Stakeholders
- Academic Research Institutes
- lipid nanoparticles’ Raw Materials Manufacturers, Vendors, and Distributors
- Contract Research Organizations (CROs)
- lipid Nanoparticles Service Providers
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensics Labs
- Government organizations
- Private research firms
- Contract development and manufacturing organizations (CDMOs)
Report Objectives
- To define, describe, and forecast the lipid nanoparticles market based on product, LNP Type, Molecule Type, application, end user, Service Type, end user (Services) and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall lipid nanoparticles market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the lipid nanoparticles market and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments in the lipid nanoparticles market, such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations
- To benchmark players within the lipid nanoparticles market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy
1 Micro markets are the further segments and subsegments of the lipid nanoparticles market included in the report
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Portfolio Assessment
- Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies.
Company Information
- Detailed analysis and profiling of additional market players (up to three).
Geographical Analysis
- A further breakdown of the Rest of Asia Pacific lipid nanoparticles market into countries
- A further breakdown of the Rest of European lipid nanoparticles market into countries
- A further breakdown of the Rest of Latin American lipid nanoparticles market into countries
- A further breakdown of the Rest of Middle East lipid nanoparticles market into countries
Growth opportunities and latent adjacency in Lipid Nanoparticles Market